Shares of Biocon Ltd rose as much as 2% on Wednesday, 21 May, after its subsidiary stated that its Japanese commercial partner has released the Ustekinumab BS Subcutaneous injection for the treatment of psoriasis vulgaris and psoriatic arthritis.
Ustekinumab BS Subcutaneous injection is a biosimilar version of the reference medicine Stelara (Ustekinumab). Biocon Biologics developed and manufactured it, while Yoshindo Inc. commercialised and sold it in Japan, according to the company’s exchange filing.
Following regulatory approval, the business entered into a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson, together known as Janssen, in April 2024 to commercialise Ustekinumab in Japan.
Biocon Biologics’ biosimilar was approved by Japan’s Pharmaceuticals and Medical Devices Agency in December 2024. Biocon Biologics previously introduced Ustekinumab in the United States and Europe in February of this year.
Biocon’s March quarter results exceeded expectations, with the generics unit leading the way. The introduction of the Revlimid generic in the United States was a major driver of growth. During the March quarter, important growth drivers included a UK-Netherlands retail tie-up for Liraglutide, as well as the launch of cancer and blood pressure treatment capsules in the US.
Biocon’s four biosimilars exceeded $200 million in sales apiece during the fiscal year 2025.
At 12:27 pm, the shares of Biocon were trading 1.80% higher at Rs 338.50 on NSE.
Wondering About Biocon Ltd? The Analyst Has Answers.
Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!
